D.E. Shaw & Co’s Jazz Pharmaceuticals JAZZ Stock Holding History

D.E. Shaw & Co’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-10,000	Closed	-$1.33M	–	4975
2022 Q3	$1.33M	Hold	10,000	–	–	﹤0.01%	3362
2022 Q2	$1.56M	Hold	10,000	–	–	﹤0.01%	3287
2022 Q1	$1.56M	Sell	10,000 -24,620	-71%	-$3.57M	﹤0.01%	3545
2021 Q4	$4.41M	Buy	34,620 +10,000	+41%	+$1.31M	﹤0.01%	2521
2021 Q3	$3.21M	Buy	+24,620	New	+$3.72M	﹤0.01%	2561
2021 Q2	–	Sell	-10,000	Closed	-$1.64M	–	4873
2021 Q1	$1.64M	Buy	+10,000	New	+$1.65M	﹤0.01%	2752
2020 Q4	–	Sell	-21,200	Closed	-$3.02M	–	4026
2020 Q3	$3.02M	Sell	21,200 -11,000	-34%	-$1.36M	﹤0.01%	2065
2020 Q2	$3.55M	Sell	32,200 -13,100	-29%	-$1.45M	﹤0.01%	1929
2020 Q1	$4.52M	Buy	45,300 +11,500	+34%	+$1.49M	0.01%	1544
2019 Q4	$5.05M	Buy	+33,800	New	+$4.6M	0.01%	1727
2017 Q2	–	Sell	-17,000	Closed	-$2.47M	–	3448
2017 Q1	$2.47M	Sell	17,000 -6,800	-29%	-$886K	﹤0.01%	1707
2016 Q4	$2.6M	Buy	23,800 +3,800	+19%	+$423K	﹤0.01%	1794
2016 Q3	$2.43M	Hold	20,000	–	–	﹤0.01%	1774
2016 Q2	$2.83M	Hold	20,000	–	–	0.01%	1681
2016 Q1	$2.61M	Hold	20,000	–	–	﹤0.01%	1698
2015 Q4	$2.81M	Buy	20,000 +10,000	+100%	+$1.39M	﹤0.01%	1868
2015 Q3	$1.33M	Buy	+10,000	New	+$1.72M	﹤0.01%	2407

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

D.E. Shaw & Co's JAZZ Position: Q2 2026 in Review

D.E. Shaw & Co reduced its Jazz Pharmaceuticals (JAZZ) stake by 71% in Q2 2026, selling an estimated $46.2M and leaving 87,075 shares worth $21M. The position accounts for 0.01% of the portfolio, ranked #1260.

D.E. Shaw & Co first reported a position in JAZZ in Q2 2013 and has held it in 41 quarters since. The position peaked at $56.4M in Q1 2026. 646 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

D.E. Shaw & Co held 87,075 shares of Jazz Pharmaceuticals worth $21M as of Q2 2026.
D.E. Shaw & Co sold 211,015 Jazz Pharmaceuticals shares in Q2 2026, an estimated $46.2M.
Jazz Pharmaceuticals made up 0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #1260 holding.
D.E. Shaw & Co first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 41 quarters since.
D.E. Shaw & Co's Jazz Pharmaceuticals position peaked at $56.4M in Q1 2026.
646 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.